Check for updates

# Changes in biochemical markers following a spinal manipulation – a systematic review update

Kesava Kovanur Sampath<sup>a,b</sup>, Loïc Treffel<sup>b,c,d</sup>, Oliver P.Thomson<sup>b,e</sup>, Jerry Draper Rodi<sup>b,e,f</sup>, Michael Fleischmann<sup>b,g</sup> and Steve Tumilty<sup>h</sup>

<sup>a</sup>Centre for Health and Social Practice, Waikato Institute of Technology, Te Pukenga, Hamilton, New Zealand; <sup>b</sup>School of Public Health, University of Technology, ARCCIM, Sydney, Australia; <sup>c</sup>Institut Toulousain d'Ostéopathie, IRF'O, Toulouse, France; <sup>d</sup>INMG-PGNM, Univ Lyon1, Lyon, France; <sup>e</sup>Research Department, University College of Osteopathy, London, UK; <sup>f</sup>National Council for Osteopathic Research, London, UK; <sup>g</sup>School of Health and Biomedical Sciences, RMIT University, Melbourne, Australia; <sup>h</sup>Centre for Health, Activity, and Rehabilitation Research (CHARR), School of Physiotherapy, University of Otago, Dunedin, New Zealand

#### ABSTRACT

**Objective:** The aim of this systematic review was to update the current level of evidence for spinal manipulation in influencing various biochemical markers in healthy and/or symptomatic population.

**Methods:** This is a systematic review update. Various databases were searched (inception till May 2023) and fifteen trials (737 participants) that met the inclusion criteria were included in the review. Two authors independently screened, extracted and assessed the risk of bias in included studies. Outcome measure data were synthesized using standard mean differences and meta-analysis for the primary outcome (biochemical markers). The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used for assessing the quality of the body of evidence for each outcome of interest.

**Results:** There was low-quality evidence that spinal manipulation influenced various biochemical markers (not pooled). There was low-quality evidence of significant difference that spinal manipulation is better (SMD -0.42, 95% Cl - 0.74 to -0.1) than control in eliciting changes in cortisol levels immediately after intervention. Low-quality evidence further indicated (not pooled) that spinal manipulation can influence inflammatory markers such as interleukins levels post-intervention. There was also very low-quality evidence that spinal manipulation does not influence substance-P, neurotensin, oxytocin, orexin-A, testosterone and epinephrine/nor-epinephrine.

**Conclusion:** Spinal manipulation may influence inflammatory and cortisol post-intervention. However, the wider prediction intervals in most outcome measures point to the need for future research to clarify and establish the clinical relevance of these changes.

# Introduction

Spinal manipulation (SM) is a specific hands-on approach used by several different healthcare disciplines commonly for the intended purposes of reducing spinal pain and reducing disability [1–5]. Early theories on the mechanisms of therapeutic effects following SM centered within a biomechanical paradigm. According to the biomechanical model, an SM can cause changes in the biomechanics of the spine which allows it to function in a more optimal state [6,7]. However, accumulating evidence clearly demonstrates a shift toward a neurophysiological paradigm [8–25]. According to the neurophysiological paradigm, a mechanical input such as an SM may trigger a cascade of neurophysiological response at both spinal and supraspinal levels [7,10,14,24].

Pain modulation following SM is a net result of complex neural interactions between various physiological systems involving different biochemical mediators [26]. Several neuropeptides such as substance-P (SP), neurotensin, oxytocin and orexin-A influence pain modulation through widespread effects in the nervous system [27,28]. As these chemicals are primarily released at the injury site, they also influence the initiation of inflammatory process. This in turn results in the production of numerous pro-inflammatory and immunoregulatory cytokines and neurotransmitters (e.g., tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ); interleukins (IL)) [29,30]. Furthermore, endogenous opioids (ex: -endorphins); hormones (e.g. cortisol) and catecholamine's (epinephrine and nor-epinephrine) modulate several immune parameters associated with the inflammatory process [31–33].

It has been hypothesized that SM activates the liberation of various biochemical markers such as SP, TNF- $\alpha$  from neural tissues resulting in its hypoalgesia

#### **ARTICLE HISTORY** Received 21 June 2023

Accepted 18 August 2023

#### KEYWORDS

Spinal Manipulation; Biochemical Markers; Pain Markers; Inflammatory Markers; Cortisol

CONTACT Kesava Kovanur Sampath 🖾 kesava.kovanursampath@wintec.ac.nz 🖻 Centre for Health and Social Practice, Waikato Institute of Technology, Te Pukenga, 51, Akoranga Road, Hamilton, New Zealand

Supplemental data for this article can be accessed online at https://doi.org/10.1080/10669817.2023.2252187.

JOURNAL OF MANUAL & MANIPULATIVE THERAPY 🕒 29

and/or anti-inflammatory effects [34]. This is based on evidence that have demonstrated that SM can influence biochemical markers such as SP [35] neurotensin and oxytocin; -endorphins [10] and hormones such as cortisol [15,36]. A systematic review undertaken by our team previously established a 'moderate' level evidence that SM may influence various biochemical markers following SM [37]. Specifically, SM can increase substance-p, neurotensin, oxytocin and interleukin levels and may influence cortisol levels postintervention [37].

Our previous systematic review [37] employed valid methods and has been widely cited suggesting that our review is current and topical. Further, since the publication of our review, there has been significant interest in this topic area with several new studies published. Taking into consideration these factors and a possibility that the level of evidence may change with the findings from new studies, we considered that it was timely to provide an update of our systematic review as recommended previously [38,39].

The aim of this systematic review update was to provide an update on:

- The effects of SM on biochemical markers in humans.
- Establish the level of evidence for changes in biochemical biomarkers following an SM.

# **Operational definitions**

Systematic review update: The update of a systematic review is defined as 'a new edition of a published systematic review with changes that can include new data, new methods, or new analysis to the previous version' [38]. This may include the following: updating the search; updating risk of bias tools; synthesis of new papers; adjusting the conclusions of a review [39].

Biochemical Markers: For the purpose of this systematic review update, biochemical markers were classified into the following three categories: (1) neuropeptides (2) inflammatory and (3) endocrine biomarkers.

# Methods

This review has been reported based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [40]. The review protocol was prospectively registered on the International Prospective Register of Systematic Reviews (PROSPERO: CRD42016049473).

# **Types of studies**

Randomized controlled trials (RCT) or controlled clinical trials that involved humans (healthy or painful), measured biochemical markers were eligible for this review. Only articles published in English language were included. Further, published conference abstracts, pilot studies and dissertations were excluded.

# **Types of participants**

Studies involving humans were eligible. There were no restrictions based on age, gender and severity of pain.

# **Types of intervention**

The intervention of interest was SM provided either by a physiotherapist, osteopath, or chiropractor. SM is defined as a high-velocity, low-amplitude thrust technique that is often associated with a cavitation [41]. The comparator (control) group could be any of the following: no intervention, usual care group, GP care, sham therapy or any other therapy.

# **Types of outcome(s)**

The outcome measures of interest included the following biochemical markers: (1) neuropeptides (e.g. neurotensin, oxytocin, SP) (2) inflammatory (e.g. TNF, IL) and (3) endocrine (e.g. cortisol, epinephrine, norepinephrine) biomarkers from any body fluids.

#### Search strategy

In consultation with a librarian, it was decided that the previous search strategy was relevant and no changes were required. A replacement approach as recommended by Cochrane was utilized where the previous review was used as one source of studies. A bibliographic search (Table 1) was performed through the following databases: Medline, AMED, EMBASE, CINAHL, SPORTSDiscus, PubMed, Cochrane Library, Web of Science, Physiotherapy Evidence Database, and SCOPUS (from inception till May 2023).

#### Data management

Articles obtained by the systematic search in the above-mentioned databases were exported to Covidence (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia; www. covidence.org) and managed in Covidence throughout the review process.

Table 1. Search strategy.

Phase	1		Phase 2		Phase 3
(1)	Exp. (manual N5 thrap*)	(1)	Exp. Biological marker	(1)	Exp. Randomized clinical trial/
(2)	Exp. "physical therap*"	(2)	Biochemical markers	(2)	Controlled clinical trial/
(3)	Exp. physical therapy modalities	(3)	Exp. Pain	(3)	Clinical study/
(4)	Exp. chiropractic	(4)	Exp. stress	(4)	Clinical article/
(5)	Exp. osteopathy	(5)	Stress biomarker	(5)	Multicenter study/
(6)	Manipulation N5 treatment	(6)	Endocrine*	(6)	random allocation/
(7)	therap* N5 manipulat*	(7)	Sympathetic nervous system	(7)	single-blind procedure/
(8)	traction manip*	(8)	Hormone	(8)	placebos/
(9)	thoracic manip*	(9)	cortisol	(9)	or/ 28-35
(10)	mobilization	(10)	oxytocin	(10)	assign*
(11)	Or/ 1-10	(11)	ß-endorphins	(11)	allocate*
		(12)	catecholamine	(12)	blind*
		(13)	neuropeptide	(13)	control
		(14)	ACTH	(14)	random*
		(15)	OR/12-25	(15)	or/ 37-41
		(16)	11AND 26	(16)	36 OR 42
				(17)	Not animal
				(18)	43 AND 44
				(19)	27 AND 45

# **Study selection**

Duplicates were automatically detected and removed by Covidence. However, one reviewer (KSK) went through the titles to ensure all duplicates were removed. Full texts of the remaining articles were then screened by two independent reviewers (KSK and LT). Any disagreements between reviewers at any stage of the selection process were resolved through consensus and discussion. A third reviewer was available if required.

#### Data extraction and management

Three reviewers (KSK, JDR and LT) collected data independently from included studies using a standardized data collection form in Covidence. The following were extracted: (1) study characteristics: funding, settings, design and country (2) patient characteristics: age, gender, severity of condition (if applicable) (3) intervention characteristics: number of intervention groups, content of each intervention (4) Outcome/data results: outcome measures (biomarkers) used, time points used and duration of follow-up (Table 2). Any disagreements were resolved by reaching a consensus.

# **Risk of bias**

The Cochrane Collaboration's tool for assessing risk of bias [42] available as part of Covidence was used by two reviewers (KSK, LT, JDR and OT) independently to assess the risk of bias in the included studies. Any disagreements were resolved through consensus. If consensus could not be obtained a third reviewer was available to enable a final decision. A study was considered to have low risk of bias if the random sequence generation, allocation concealment and incomplete outcome data domains were adequately met. While the use of the recent Cochrane's risk of bias (RoB 2) tool [43] has been encouraged, it was not mandatory to use RoB-2 for a review update.

#### **Summary measures**

Meta-analyses were performed where it was appropriate to pool data from multiple studies at two time points (1) immediate and (2) short-term. For the purpose of this review, immediate was defined as the measurement point immediately (up to 30 minutes) after intervention and short-term was defined as the measurement point up to 24 hours after intervention. Mean and standard deviations for outcome measures were extracted into Cochrane's online Review Manager (RevMan Web, version 1.22.0) [44] software to analyze the comparative data between each intervention effect.

#### Measures of treatment effects

All outcomes of interest were examined as a standardized mean difference (SMD) and a random effects model was used whereby the overall effects are adjusted to include an estimate of the degree of variation or heterogeneity across studies. An effect size (Cohen's d; small – 0.2; medium – 0.5 and large – 0.8) [45] and a 95% confidence interval were calculated for each treatment comparison.

#### Dealing with missing data

The authors were contacted in cases of missing data. For data that were graphically displayed, a software

Table 2. Character	ristics of included studies.				
Author, year	Methods/participant characteristics	Intervention	Outcome Measure(s)/ time points	Findings	Notes
Achalandabaso2014	1 3 groups RCT	Placebo SM vs SM (cervical-Thoracic)	Blood samples (plasma and serum)	No changes in any of the studied damage markers	
	Randomized: 30 healthy subjects volunteers	Placebo SM Control group: n=10 received following the cervical manipulation protocol with regard to hand contact, without intention of mobilization, nor application of tissue tension by the operator	CPK, LDH, CRP, Troponin-I, Myoglobin, NSE, aldolaseBefore and right after intervention and 2 hours after		
	Gender: 16 male – 14 female subjects	<b>Cervical group</b> : n=10 received HVLA thrust at C4 and C5 cervical spine in supine, with left rotation and right-side bending			
	Age: 27.6 - 29.8 - 28.6 (y, mean 3 groups Ctrl, Cerv, Th)	Thoracic Manipulation: n=10 received HVLA thrust at levels T3-T4 and T4-T5			
	Settings: healthy students from the University of Jaen				
Brennan 1991	3 groups RCT.	SM (vs) sham (vs) soft tissue	plasma concentration	↑ SP in SM group	Funded by a grant from the Foundation for Chiropractic Education and Peccarch
	Randomised: 99 healthy volunteers.	SMT group: 42 participants received a thoracic SMT (71 to aT6)	CBC		
	Gender: 67 males, 32 females	<b>Sham group:</b> 38 participants received sham manipulation (low velocity, low amplitude thrust).	SP		
	Age: 26.2 (mean)	Soft tissue group: 19 participants received soft tissue manipulation to either the left or right gluteal area.	15 minutes pre and 15 minutes post- intervention		
	Setting: Research department, Chiropractic college.	2			
Christian 1987	4 groups RCT.	Pain-free SM group (vs.) pain SM group (vs.) pain-free sham group (vs.) pain sham group.	Plasma samples	No changes in any outcome measures	Supported by a grant-in aid from NHMRC, Australia
	Randomised: 40. 20 with pain and 20 pain- free. Gender: only male participants	Pain-free SM group: 10 asymptomatic participants received chiropractic SMT. Pain SM group: 10 participants with pain received chiropractic SMT.	Cortisol ACTH		
	Age: 18 to 30 (range)	Pain-free sham group: 10 asymptomatic participants received sham intervention where a very slight pressure was exerted on the neck.	ß-endorphin		
	Setting: chiropractic teaching clinic	Pain sham group: 10 participants with pain received sham intervention.	Pre-intervention, 5 and 30 minutes post- intervention.		
					(Continued)

Table 2. (Continu	ued).				
Author, year	Methods/participant characteristics	Intervention	Outcome Measure(s)/ time points	Findings	Notes
Duarte2022	3 groups RCT99 healthy young adults mostly chiropractic studentsGender: 10 female – 89 maleAge: 25.6 years (mean) Setting: Canadian Memorial Chiropractic College Simulation Laboratory and Life Science Laboratory	Spinal manipulation therapy vs ControlSingle intervention <b>Control</b> (preload only): n= 33 <b>Single thoracic SMT</b> with a total peak force of 400N: n=33 <b>Single thoracic SMT</b> with a total peak force of 800N: n=33	14 different inflammatory biomarkers (pro, anti, dual role, chemokine, and growth factor) was assessed by multiplex arrayGM-C5FIFN-ylL-1G, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL- 13, IL-17A, IL-23TNF-a	Select plasma pro-inflammatory and dual-role - cytokines were elevated by higher compared to lower SMT force btw-group (800N vs 400N) difference was observed on interferon- gamma, IL-5, IL-6, while a within-group difference (800N: immediately vs 20 minutes nost-intervention) was observed on IL-6.	This research project was funded by the Internal Research Support Fund at Canadian Memorial Chiropractic College
Kovanur Sampath2017	RCT:2 Groups	Thoracic SM vs Sham	Salivary Cortisol	Thoracic SM resulted in an immediate decrease line salivary cortisol concentration and reduced T/C ratio 6h after intervention.	Funded by a grant from the New Zealand Manipulative Physiotherapists Association
	24 healthy men	SM: n=12 received HVLA thrust at T5 vertebra	Salivary Testosterone	SM did not differentially alter oxyhemoglobin, testosterone, or HRV vs responses in the sham group	
	Age: 18-45 y Setting: Controlled laboratory study	upon expiration (single thrust) <b>Sham</b> : n=12 same setup without HVLA thrust	T/C Ratio HRV Oxyhemoglobin concentration (right calf muscle) Before, at 5 minutes, 30 minutes and approximately 6 hours after intervention		
Kovanur Sampath2021	Randomized 2-sequence, 2-period crossover trial	SM vs sham 2 session in cross-over	Salivary samples	Statistically significant condition by time interaction was found for the T/C ratio (mean difference: $-0.16$ CI: $-0.33$ to $0.06$ ; $P < .05$ ) and TOI (mean difference: $1.35$ ; CI: $-1.3$ to $4.1$ ; P < .05) of caff muscle but not for Achilles tendon ( $P = .6$ ); No difference was found for heart rate variability ( $P = .5$ )	Funded by a grant from the New Zealand Manipulative Physiotherapists Association
	24 participants with Achilles tendinopathy >3mo	Sequence 1 (sham intervention and then thoracic spinal manipulation) or sequence 2 (thoracic spinal manipulation and then sham intervention)	T/C Ratio (Salivary samples)		
	Age: 48 ±7 y Gender: Male: 10 ; Female: 14	Session duration : 10 seconds SM: n=24 received thoracic spinal manipulation HVLA on T5 vertebra upon expiration	HRV (/ECG) Total oxygenation index calf muscle and Achille tendon (/near-infrared spectroscopy)		
	Setting: University Laboratory with washout period of 1week	Sham intervention: n=24 received same setup, not place a fixating hand against thoracic spine and without HVLA thrust	TC Ratio: Pre-intervention, at 5 minutes, 30 minutes, and 6 hours post- intervention		
					(Continued)

32 🛞 K. KOVANUR SAMPATH ET AL.

Table 2. (Continu	ied).				
Author, year	Methods/participant characteristics	Intervention	Outcome Measure(s)/ time points	Findings	Notes
Lohman 2019	RCT 2 groups	Cervical SM vs sham CSM	Serum concentration using the Milliplex Map Magnetic Bead Panel Immunoassay on the Luminex 200 Platform	CSM group, significant increases in pre vs post- Sup manipulation mean oxytocin (154.5±60.1 vs L 185.1±75.6, p= .012); neurotensin (116.0 ±26.5 vs.136.4±34.1, p< .001); orexin A (52.2 ±31.1 vs 73.8±38.8, p< .01) but no significant differences in mean cortisol (p= .052) (Serum concentration)	ported by Loma inda University.
	Randomized 28 female subjects with non- specific mechanical neck pain	One session	Oxytocin		
	Age: 37.1 – 30.1 (CSM – Sham)	<b>CSM</b> : n=13 received a cervical spine manimulation HVI A thrust in rotation	Neurotensin		
	Setting: Loma Linda University	Sham CSM: n=15 received sham CSM without moving the individual or carrying out the final thrust procedure	Orexin A		
			Cortisol		
Molina-Urtega 2014	4 3 groups RCI Randomised: 30 healthy volunteers	Control (vs) Cervical SM (vs) Thoracic SM Control group: 10 participants received no intervention.	Serum samples NO2	T SP, T PPI in CSM group No effects on NO2	
	Gender: 16 male, 14 female	Cervical manipulation group: 10 participants received cervical manipulation.	SP		
	Age: 27.8 (mean)	Thoracic manipulation group: 10 participants received thoracic manipulation.	PPT (Algometer)		
	Setting: University Research Department		Pre-intervention, immediately after and 2 hours post-intervention.		
Pascual-Vaca2017	Randomized controlled blinded clinical study	The experimental group (EG, n=23) received a spinal manipulation of the thoracolumbar junction, and the control group (CG, n=23) received a sham procedure	PPT algometer (spinous process T10 to L1 and quadratus Lumbarum)Urinary pH	significant changes in PPT in both quadratus lumborum (P<0.001) as well as in the spinous processes of all of the evaluated levels (P<0.05). No changes in urinary pH were observed ( $P=0.419$ )	
	46 patients suffering from renal lithiasis ; 27 men (59%) and 19 women (41%) with an average age of 38.5 (SD=6.80) and a Body Mass Index (BMI) of 25.07 (SD=3.12)	EG: High speed movement with low amplitude, bilaterally on T12-L1 at the end of ROM rotating patient	Pre-Post (immediately after intervention)		
	Settings/location: Nephrology Departments of 2 hospitals and one private consultancy of physiotherapy in Valencia (Spain)	CG: The therapist placed one hand on the sacrum and the other hand on the middle thoracic region, without performing any action for 90 seconds. A rest time of 10			
		minutes was also taken before taking the post intervention measurements.			
					(Continued)

Table 2. (Continu					
Author, year	Methods/participant characteristics	Intervention	Outcome Measure(s)/ time points	Findings	Notes
Plaza-Manzano 2014	3 groups RCT.	Control (vs.) cervical manipulation (vs.) thoracic manipulation	Serum samples	t neurotensin, t oxytocin in CSM and TSM aroups immediately.	
	Randomised: 30 healthy participants.	Control group: 10 participants received no intervention.	neurotensin	f cortisol in CSM group immediately.	
	Gender: 16 males, 14 females	Cervical manipulation group: 10 participants received cervical manipulation.	oxytocin	No changes in orexin-A.	
	Age: 27.8 (mean)	Thoracic manipulation group: 10 participants received thoracic manipulation.	orexin A		
	Setting: University Research setting.		cortisol. Samples were collected before, immediately after and 2 hours after		
Puhl 2012	2 group RCT.	SMT (vs.) Sham.	manipulation. Plasma samples	No changes in E or NE levels.	Only 36 included in final
	Randomised: 56 healthy participants.	<b>SMT group</b> : 18 participants received a thoracic SMT.	NE		anarysis. 2 subjects developed adverse reaction
					(vertigo) post- randomisation during catheter insertion.
	Gender: 19 males, 17 females.	Sham group: 18 participants received sham manipulation (identical setup like SMT but without the thrust).	ш		No adverse events after intervention
	Age: 26.1(mean).		Pre-intervention, immediately after and 15 minutes post-intervention.		Funded by Research division, Canadian Memorial Chiropractic College
Teodorczyk-Injeyan 2006	Setting: Chiropractic teaching clinic. 3 groups RCT.	SMT (vs.) Sham (vs.) control.	Serum samples	$\downarrow~$ IL-1 <sup>B</sup> No effects on TNF- $\alpha$ or SP	Funded by Public Health Services Grant, Canada
	Randomised: 64, healthy participants	<b>SMT group</b> : 24 participants received a thoracic SMT.	TNF-α		5
	Gender: 28 males, 36 females	Sham group: 20 participants received sham manipulation (identical setup like SMT but without the thrush.	SP		
	Age: 24.7 (mean)	<b>Control group</b> : participants (n=20) did not receive any treatment.	IL-1		
	Setting: Chiropractic College		Pre-intervention, 20 minutes and 2 hours post-intervention.		
					(Continued)

Table 2. (Continu	ed).				
Author, year	Methods/participant characteristics	Intervention	Outcome Measure(s)/ time points	Findings	Notes
Teodorczyk-lnjeyan 2010	3 groups RCT.	SMT-C (vs.) SMT-NC (vs.) control.	Serum samples	† IgG, † IgM in SM-C group at 20-minutes and F 2 hours post-intervention.	Funded by Public Health Services Grant, Canada
	Randomised: 74 healthy participants	SM with cavitation group: 27 participants received a thoracic SMT with an audible cavitation.	PBMC		
	Gender: 31 males, 43 females	SM without cavitation: 25 participants received sham manipulation (identical setup like SMT but without cavitation).	19G		
	Age: 24.7 (mean)	<b>Control group</b> : participants (n=22) in this group did not receive any treatment.	Mgi		
	Setting: Chiropractic College		Pre-intervention, 20 minutes and 2 hours post-intervention.		
Valera-Calero2019	3 groups RCT	Cervical manipulation vs cervical mobilization vs sham manipulation in patients with chronic mechanical neck pain.	salivary cortisol levelsPre-Post intervention	A significant and comparable increase in cortisol levels was observed immediately after cervical manipulation and mobilization (both P<0.001)	
	83 patients with chronic mechanical neck pain	<b>Cervical spine manipulation</b> (n=28) velocity, mid-range, left rotational force to C5-C6, with right side bending and left rotation	_	Reduced neck pain and decreased disability immediately after manipulation.	
	<b>Age</b> : Mean±SD	<b>Cervical mobilization</b> (n=28) grade III postero- anterior joint oscillatory mobilization technique applied to the articular pillar of C5/ 6 on the subject's symptomatic side			
	cMAN 35.64±8.11	Sham manipulation (n=27) eliminated the joint preload and thrust component			
	cMOB 37.25±10.54 Sham 36.96±8.89 Gender : 51 women, 32 men Setting: University of Alcala de Henares: outpatient (referrals from office workers)				
Whelan 2002	3 groups RCT.	<b>Control Group</b> : 10 participants were just supine lying. No manipulation or vertebral positioning done.	Salivary samples	No effects on basal cortisol levels.	Supported by New York Research Committee
	Randomised: 30 healthy student volunteers	Sham group: 10 participants were lying supine with their cervical spine positioned but without any manipulation.	Cortisol		
	Gender: only male participants	<b>CM Group</b> : An upper cervical manipulation was performed on 10 participants.	5 consecutive weeks.		
	Age: unavailable		Week-1: 5 consecutive days.		
	setting: kesearch Department, Uniropractic college.		week 2-5: pre-intervention, 5 and 60 minutes after intervention		
Note: ACTH – Adrenc	o-Corticotropic Hormone, C – Control, CSM – Ce	ervical Spinal Manipulation, I – Intervention, Ig – II	mmunoglobulin, lL – Interleukin, NO2 – Nitr	ic Oxide, PBMC – Peripheral Blood Mononuclear C	Cells, PPT – Pressure Pain

Threshold, SM – Spinal Manipulation, SM-C – Spinal Manipulation, with Cavitation, SM-NC – Spinal Manipulation with No Cavitation, SP – Substance-P, ST – Soft Tissue, TSM – Thoracic Spinal Manipulation, TNF – Tumour Necrosis Factor, VC – Venipuncture Control.

#### 36 👄 K. KOVANUR SAMPATH ET AL.



Figure 1. PRISMA diagram of included studies.

tool (https://automeris.io/WebPlotDigitizer/) was used, which is consistent with the original review.

# Assessment of heterogeneity

Clinical heterogeneity was evaluated by determining if different clinical factors (characteristics of participants, interventions, outcome measure) varied between trials and could potentially influence the treatment effect. Statistical heterogeneity was determined using Chisquare and I [2] statistics (25%, 50% and 75% representing low, moderate and high heterogeneity respectively). If the heterogeneity was more than 50% (representing moderate heterogeneity), a sensitivity analysis was conducted to identify the cause of statistical heterogeneity.

# **Prediction interval**

We calculated prediction interval (PI) as I2 statistics may not point to the clinical implications of the observed heterogeneity. The PI represents interval within which the effect size of a new study would fall if the new study was randomly selected from the same



Funnel plot has been recommended to assess publication bias in included studies. However, the funnel plot was not performed as the required statistical conditions were not met (10 or more studies).

# **Data synthesis**

The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system [50] was used to determine the overall quality of the evidence (high, moderate, low and very low).

# Results

An updated search retrieved a total of 1466 records. After removal of duplicates, 1043 records were screened. Of the 12 full-text records that were assessed for eligibility, a total of seven studies that met the inclusion criteria were included in review. Together with the eight studies from the original review, a total of 15 studies were part of this systematic review update (refer Figure 1)

# Summary of included studies

A full description of included studies has been provided in the 'characteristics of included studies' (refer Table 1).

### **Methods**

Out of 15 studies [15,18–21,35,36,51–58], nine studies were RCTs with three groups [21,35,36,51,52,54,56–58] five studies were RCTs with two groups [15,18–20,55] and one study had four groups [53].

#### Sample size

A total of 737 participants were examined in the studies. The sample size in the included studies ranged from 30 to 99 with only five studies recruiting more than 50 participants. All studies recruited participants in a single center.

#### **Participants**

The mean age of participants across all studies was 29.7 years. While 11 studies [15,20,21,35,51,53–58] included both male and female participants; three studies [19,36,52] included only male participants; and one study [18] included only female participants. Of the 15 studies, ten included healthy volunteers [15,19,21,35,36,51,52,54,56,57], four

**Figure 2.** Risk of bias in included studies. Note: Molina-Ortega 2014 and 2014a are one study; Plaza-Manzano 2014 and 2014a are one study.

population of studies that are included in the metaanalysis [46]. Reporting a prediction interval in addition to the summary estimate, CI and I2 statistics have been recommended to capture the range of true effects that can be expected in future settings [47,48]. The formula to calculate PI is available [49] however, a pre-set template that is available from www.meta-analysis. com was used for calculating PIs in this review.

Table 3. Summary of findings (GRADE).

Spinal manipulation compared to Control/Sham in influencing biochemical markers

Patient or population: healthy or symptomatic participants Settings: Primary care, outpatient, community Intervention: Spinal Manipulation Comparison: Control/sham

Biochemical markers (follow up: mean 2 hours; assessed with: plasma or serum or saliva)

			ainty assessment					N <sup>o</sup> of patients	Effe	ect	
Nº of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	[SM]	[Other Intervention]	Relative(95% Cl)	Absolute(95% CI)	Certainty
15	randomised trials	not serious	serious <sup>a</sup>	serious <sup>b</sup>	not serious	None	357	380	ı	see comment	2A0100Low
Note: Cl: confider Explanations. Known Heterogei Different settings.	nce interval. neity across studies, no /context/outcome mea:	t pooled. sures.									

38 😸 K. KOVANUR SAMPATH ET AL.



(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 3. Forest plot of comparison: SM vs control/sham, outcome: Substance-P (immediate).

[18,20,53,58] included participants with pain (3 with neck pain and 1 with Achilles tendinopathy) and one study incuded participants with renal lithiasis.

# Interventions

Two interventions were used by the researchers (1) cervical spine manipulation (either directed to atlanto-axial joint or cervical spine) (2) thoracic spine manipulation (either directed to T1 to T6, T12 or at the therapist's discretion). In eight out of 15 studies (53%), thoracic spinal manipulation was the intervention used [15,19–21,52,54,55,57]. Four out of 15 studies (27%) used cervical manipulation [18,36,53,58] as the intervention and three out of 15 studies (20%) made use of both cervical and thoracic spinal manipulation interventions. While low velocity low amplitude thrust (mobilization) or setup for a thrust without manipulation was the commonly used sham procedure (n = 8), touch with no pressure was used as control (n = 7).

#### **Outcome measures**

A diverse range of outcome measures were reported in the studies including SP, neurotensin, cortisol, epinephrine/nor-epinephrine, interleukins, TNF, oxytocin and orexin-A. Most studies provided follow-up assessments at two time points: immediately (up to 30 minutes) and short-term (hours) after intervention.

### Safety

Only one study [15] reported about withdrawal/ adverse events. Another study [51]investigated

changes in tissue damage markers after a spinal manipulation, which can be considered as an investigation about safety of spinal manipulation. Other studies did not report the presence/absence of adverse events and/or safety of spinal manipulation.

# **Risk of bias in included studies**

The risk of bias was analyzed for all individual studies. Figure 2 provides a summary of the judgments of each methodological quality item for each study except for one study [53], random sequence generation was adequate in all other studies. Allocation concealment was considered 'unclear' in four studies [21,36,51,52] 'inadequate' in two studies [18,53] and 'adequate' in nine studies [15,19,20,35,54-58]. In manual therapy studies, blinding of participants and practitioners may not be possible. Hence all studies were rated as either 'high' risk or 'unclear' risk for this domain. Blinding of outcome assessors was explicit and considered 'low' risk in four studies [19,20,55,58], 'unclear' risk in eight studies [15,21,35,36,52,53,56,57] and 'high' risk in three studies [18,51,54]. Except for one study [15] in which participants withdrew post randomization, attrition bias was not detected in other studies. One study [58] was rated 'high risk' for other bias as there was considerable deviation from the study protocol. Of the 15 studies, 10 studies [15,18-21,36,52-54,57] received either full or partial funding. Five studies [35,51,55,56,58] did not report source of funding. One study [53] was rated 'high risk' overall as it did not meet random sequence generation and allocation concealment criteria.

Table 4. Summary of findings (GRADE).

Spinal manipulation compared to Control/Sham in influencing neuropeptides and inflammatory biomarkers

Patient or population: Healthy or symptomatic participants Settings: Primary care, outpatient, community Intervention: Spinal Manipulation Comparison: Control/sham

comparison: contro	l/snam										
			Quality assessm	ient			N <sup>⁰</sup> of patient:			Effect	
Nº of studies Study	' design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Spinal Manipulation	Control	Relative(95% Cl)	Absolute(95% Cl)	Quality
Substance-P, immec	diate change:	s (assessed w	vith blood)								
3 rando	mised trials	not serious	not serious	not serious	very serious <sup>1</sup>	none	56	69	ı	SMD 0.71 lower(1.22 lower to 0.22 lower)	$MOI_{\infty} \oplus \oplus$
Substance-P, short-	term change:	s (assessed w	vith blood)								
2 rando	mised trials	not serious	serious <sup>2</sup>	not serious	serious <sup>3</sup>	none	44	60	ı	SMD 1.16 fewer(2.53 lower to 0.21 higher)	⊕ ******
Neurotensin (assess	ed with: Blo	od)									
2 rando	mised trials	not serious	not serious	not serious	very serious	none	33	35		SMD 0.52 lower(1.01 lower to 0.03 lower)	⊕ <sup>•••</sup> VERYLOW
Oxytocin (assessed)	with: Blood)										
2 rando	mised trials	not serious	not serious	not serious	very serious <sup>4</sup>	none	33	35	ı	SMD 0.47 lower(1 lower to 0.06 higher)	⊕ ™VERYLOW
Orexin-A (assessed wi	ith: Blood)										
2 rando	mised trials	not serious	not serious	not serious	very serious <sup>4</sup>	none	33	35	·	SMD 0.47 lower(1 lower to 0.06 higher)	⊕ <sup>•••</sup> VERYLOW
Inflammatory Biomar	kers (TNF, IL-2	2; assessed wi	th: Blood)								
4 rando	mised trials	not serious	serious <sup>5</sup>	not serious	not serious	none	107	85	-	See comment	MOl∞ ⊕ ⊕
Note: Cl: Confidence ir <sup>1</sup> Granhical data retrievo	nterval; SMD: 5	Standardised	mean difference								
<sup>2</sup> Heterogeneity = $86\%$	במ מזוונה הסו	אמר מומ שר	in parca.								
<sup>3</sup> Sample size < 100. Fi	ndings based	on single stu	dy.								
<sup>-</sup> Sample size < 100	:										
<sup>3</sup> Known Heterogeneity	/, studies not	pooled									

Table 5. Summary of findings (GRADE).

Spinal manipulation compared to Control in influencing endocrine markers

Patient or population: Healthy Settings: Primary care, outpatien Intervention: Spinal Manipulatio Comparison: Control	' or symptomatic nt, community on	: participants								
		Quality assessm	ent			N <sup>⁰</sup> of patients			Effect	
N <sup>g</sup> of studies Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Spinal Manipulation	Control	Relative(95% Cl)	Absolute(95% CI)	Quality
<b>Cortisol, immediate changes</b> (: 7 randomised trials	assessed with l not serious	<b>blood or saliva)</b> serious	not serious	Serious <sup>2</sup>	none	114	115	ı	SMD <b>0.42 lower</b> (-0.74 lower to -0.1 lower)	MO1₀⊕⊕
<b>Cortisol, short-term changes</b> ( 4 randomised trials	assessed with k not serious	<b>blood or saliva)</b> Serious <sup>3</sup>	not serious	Serious <sup>4</sup>	none	63	63	ı	SMD 0.45 lower(-0.79 lower to 0.1 lower)	MOl∞ ⊕ ⊕

i

33

33

none

very serious<sup>3</sup>

not serious

 Testosterone (assessed with: saliva)

 2
 randomised trials not serious serious

ï

33

33

none

very serious<sup>3</sup>

not serious

Note: CI: Confidence interval; SMD: Standardized mean difference.

<sup>1</sup>Sample size < 100. <sup>2</sup>Heterogeneity. <sup>3</sup>Sample size < 50. Findings based on single study.

randomised trials not serious serious

Testosterone (assessed with: saliva)

2

SMD -0.01 lower(-0.14 lower to 0.12 higher)  $\oplus$  <sup>oov</sup>VERYLOW

⊕ ∞
VERYLOW

SMD -0.04 lower(-0.06 lower to 0.14 higher)

	Spinal Ma	anipulatio	n (SM)	Cont	rol or Sh	am		Std. mean difference	Std. mean difference	Risk of Bias	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEF	G
Christian 1988	-11.5	4.7	10	-9.6	3.8	10	11.3%	-0.43 [-1.31 , 0.46]		• • • ? • •	?
Lohman 2019	10.8	7.18	13	13.97	6.84	15	12.9%	-0.44 [-1.19, 0.31]			•
Plaza-Manzano 2014	-14.2	3.8	10	-9.6	3.1	10	10.3%	-1.27 [-2.25 , -0.29]			•
Plaza-Manzano 2014a	-10.1	3.67	10	-9.6	3.1	10	11.4%	-0.14 [-1.02, 0.74]			
Sampath 2017	-0.93	0.29	12	-0.73	0.32	12	12.0%	-0.63 [-1.46 , 0.19]		• • • • • •	•
Sampath 2021	4.01	1.76	21	4.46	2.73	21	14.8%	-0.19 [-0.80, 0.41]		• • • • • •	•
Valera-Calero 2019	-0.73	0.05	28	-0.64	0.05	27	14.5%	-1.77 [-2.41 , -1.14]	_ <b>—</b>		•
Whelan 2002	-13.3	7.4	10	-10.7	10	20	12.8%	-0.27 [-1.04 , 0.49]			•
Total (95% CI)			114			125	100.0%	-0.65 [-1.10 , -0.20]	•		
Heterogeneity: Tau <sup>2</sup> = 0.1	26; Chi <sup>2</sup> = 18	8.69, df = 1	7 (P = 0.00	09); I <sup>2</sup> = 63	%				•		
Test for overall effect: Z =	= 2.84 (P = 0	0.005)							-2 -1 0 1 2	-	
Test for subgroup differe	nces: Not ap	plicable							Favours [SM] Favours [Ot	her Intervention]	

#### Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

#### Figure 4.

	Spinal Ma	anipulatio	n (SM)	Cont	rol or Sh	am		Std. mean difference	Std. mean difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
× Christian 1988	-11.5	4.7	10	-9.6	3.8	10	0.0%	-0.43 [-1.31 , 0.46]		
<ul> <li>Lohman 2019</li> </ul>	10.8	7.18	13	13.97	6.84	15	17.6%	-0.44 [-1.19 , 0.31]		
✓ Plaza-Manzano 2014	-14.2	3.8	10	-9.6	3.1	10	10.4%	-1.27 [-2.25 , -0.29]		
✓ Plaza-Manzano 2014a	-10.1	3.67	10	-9.6	3.1	10	13.0%	-0.14 [-1.02 , 0.74]		
<ul> <li>Sampath 2017</li> </ul>	-0.93	0.29	12	-0.73	0.32	12	14.7%	-0.63 [-1.46 , 0.19]		
<ul> <li>Sampath 2021</li> </ul>	4.01	1.76	21	4.46	2.73	21	27.2%	-0.19 [-0.80 , 0.41]		
X Valera-Calero 2019	-0.73	0.05	28	-0.64	0.05	27	0.0%	-1.77 [-2.41 , -1.14]		
✓ Whelan 2002	-13.3	7.4	10	-10.7	10	20	17.2%	-0.27 [-1.04 , 0.49]		8 ? 8 ? 8 8
Total (95% CI)			76			88	100.0%	-0.42 [-0.74 , -0.10]	•	
Heterogeneity: Tau <sup>2</sup> = 0.00;	; Chi <sup>2</sup> = 4.22	, df = 5 (P	= 0.52); l <sup>a</sup>	2 = 0%					•	
Test for overall effect: Z = 2	2.60 (P = 0.0	09)							-2 -1 0 1 2	_
Test for subgroup difference	es: Not appl	icable							Favours [SM] Favours [Ot	ner Intervention]

#### **Risk of bias legend**

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)

(G) Other bias

Figure 4. Forest plot of comparison: SM vs control/sham, outcome: Cortisol (immediate). Forest plot of comparison (sensitivity analysis): SM vs control/sham, outcome: Cortisol (immediate).

#### **Effects of interventions**

A summary of findings table was created to summarize the overall quality of evidence using GRADE (Tables 3–5).

# Spinal manipulation (vs) control/sham in influencing biochemical markers

Data from 15 studies (total of 737 participants) [15,18–21,35,36,51–58] (not pooled) demonstrated a 'low' quality evidence that SM was better than control in eliciting changes in biochemical markers (Table 3).

# Spinal manipulation (vs.) control/sham in influencing neuropeptides

Data from three studies (125 participants) [15,35,52] showed (Figure 3) that there was a 'very low' quality

evidence of no difference that SM is better than control/ sham (SMD –0.71, 95% CI – 1.22 to – 0.22; PI: –2.33 to 0.91) in increasing SP levels immediately after intervention. Although, the effect size and associated CIs indicate statistical significance, the prediction intervals are wide and point to lack of clear benefit from SM. Further, there was 'very low' quality evidence from two studies (104 participants) of no significant difference that SM is better than control (SMD –01.16, 95% CI – 2.53 to 0.21) (Table 4) in eliciting changes in SP levels at short-term after intervention. Between-study heterogeneity was high (86%).

There was 'very low' quality evidence from two studies (68 participants) [18,56] of no significant difference that SM is better than control/sham (SMD –0.52, 95% CI – 1.01 to – 0.03; PI – 3.69 to 2.65) in increasing neurotensin after intervention. Although, the effect size and associated CIs indicate statistical significance, the

	Spinal Ma	anipulatio	n (SM)	Cont	rol or Sh	am		Std. mean difference	Std. mean difference		F	lisk	of	Bias	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	Α	в	С	D	Е	FG
1.7.1 Thoracic Spine															
✓ Plaza-Manzano 2014a	-10.1	3.67	10	-9.6	3.1	10	13.0%	-0.14 [-1.02 , 0.74]		•	Đ	•	?	Đ	••
<ul> <li>Sampath 2017</li> </ul>	-0.93	0.29	12	-0.73	0.32	12	14.7%	-0.63 [-1.46 , 0.19]		•	•	•	÷	÷	••
<ul> <li>Sampath 2021</li> </ul>	4.01	1.76	21	4.46	2.73	21	27.2%	-0.19 [-0.80 , 0.41]		•	Ŧ	•	÷	÷	••
Subtotal (95% CI)			43			43	54.8%	-0.30 [-0.73 , 0.13]	•						
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 0.87	', df = 2 (P	= 0.65); la	<sup>e</sup> = 0%					•						
Test for overall effect: Z = 1	.37 (P = 0.1	7)													
1.7.2 Cervical Spine															
× Christian 1988	-11.5	4.7	10	-9.6	3.8	10	0.0%	-0.43 [-1.31 , 0.46]		•	•	•	?	•	+ ?
<ul> <li>Lohman 2019</li> </ul>	10.8	7.18	13	13.97	6.84	15	17.6%	-0.44 [-1.19 , 0.31]		٠	•	?	•	•	••
<ul> <li>Plaza-Manzano 2014</li> </ul>	-14.2	3.8	10	-9.6	3.1	10	10.4%	-1.27 [-2.25 , -0.29]		•	÷	•	?	÷	••
X Valera-Calero 2019         -0.73         0.05         28           ✓ Whelan 2002         -13.3         7.4         10           Subtotal (95% Cl)         33				-0.64	0.05	27	0.0%	-1.77 [-2.41 , -1.14]		•	•		•	•	? 🖨
✓ Whelan 2002 -13.3 7.4 10 - Subtotal (95% CI) 33				-10.7	10	20	17.2%	-0.27 [-1.04 , 0.49]		•	?	•	?	•	••
Subtotal (95% CI)			33			45	45.2%	-0.59 [-1.13 , -0.04]	•						
Heterogeneity: Tau <sup>2</sup> = 0.06;	Chi <sup>2</sup> = 2.66	6, df = 2 (P	= 0.27); l <sup>2</sup>	= 25%					-						
Test for overall effect: Z = 2	.11 (P = 0.0	4)													
Total (95% CI)			76			88	100.0%	-0.42 [-0.74 , -0.10]	•						
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 4.22	2, df = 5 (P	= 0.52); 12	= 0%					•						
Test for overall effect: Z = 2	.60 (P = 0.0	009)							-2 -1 0 1 2						
Test for subgroup difference	es: Chi <sup>2</sup> = 0.	.67, df = 1	(P = 0.41)	$ ^{2} = 0\%$				Favours	[experimental] Favours [control	]					
Risk of bias legend (A) Random sequence gen	eration (sele	ection bias	)												

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 5. Subgroup analysis (thoracic vs cervical manipulation). Outcome: cortisol (immediate).

prediction intervals are wide and point to lack of clear benefit from SM. However, 'very low' quality evidence from two studies (68 participants) [18,56] demonstrated no significant difference between SM and control/sham (SMD -0.47, 95%Cl - 1 to 0.06) in influencing oxytocin and orexin-A (SMD -0.59, 95% CI - 1.48 to 0.29).

# Spinal manipulation (vs.) control in influencing inflammatory biomarkers

Data were extracted from four studies (192 participants; not pooled) that compared the effectiveness of SM with control on inflammatory biomarkers such as interleukins. There was 'low' quality evidence that SM

	Spinal Manipulation (SM)			Control or Sham				Std. mean difference	Std. mean difference	Risk of Bias						
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	Α	в	с	D	Е	F	G
1.8.1 Increased Cortisol																
<ul> <li>Christian 1988</li> </ul>	-11.5	4.7	10	-9.6	3.8	10	11.3%	-0.43 [-1.31 , 0.46]		•	•	•	?	•	•	?
<ul> <li>Plaza-Manzano 2014</li> </ul>	-14.2	3.8	10	-9.6	3.1	10	10.3%	-1.27 [-2.25 , -0.29]		٠	÷	•	?	•	•	Ð
✓ Plaza-Manzano 2014a	-10.1	3.67	10	-9.6	3.1	10	11.4%	-0.14 [-1.02 , 0.74]		•	÷	•	?	•	•	Ð
✓ Valera-Calero 2019	-0.73	0.05	28	-0.64	0.05	27	14.5%	-1.77 [-2.41 , -1.14]		•	÷	•	•	•	?	Ð
✓ Whelan 2002	-13.3	7.4	10	-10.7	10	20	12.8%	-0.27 [-1.04 , 0.49]		•	?	•	?	•	•	Ð
Subtotal (95% CI)			68			77	60.2%	-0.80 [-1.49 , -0.10]								
Heterogeneity: Tau <sup>2</sup> = 0.45;	Chi <sup>2</sup> = 14.4	8, df = 4 (	P = 0.006)	; l² = 72%					-							
Test for overall effect: Z = 2	2.25 (P = 0.0	2)														
1.8.2 Reduced Cortisol																
<ul> <li>Lohman 2019</li> </ul>	10.8	7.18	13	13.97	6.84	15	12.9%	-0.44 [-1.19, 0.31]		•	•	?	•	•	•	Ð
<ul> <li>Sampath 2017</li> </ul>	-0.93	0.29	12	-0.73	0.32	12	12.0%	-0.63 [-1.46 , 0.19]		•	Ŧ	•	•	•	•	Đ
<ul> <li>Sampath 2021</li> </ul>	4.01	1.76	21	4.46	2.73	21	14.8%	-0.19 [-0.80 , 0.41]		•	÷	•	÷	•	•	Đ
Subtotal (95% CI)			46			48	39.8%	-0.37 [-0.78 , 0.04]	•							
Heterogeneity: Tau <sup>2</sup> = 0.00;	Chi <sup>2</sup> = 0.75	, df = 2 (P	= 0.69); P	= 0%					•							
Test for overall effect: Z = 1	.79 (P = 0.0	7)														
Total (95% CI)			114			125	100.0%	-0.65 [-1.10 , -0.20]	•							
Heterogeneity: Tau <sup>2</sup> = 0.26;	Chi <sup>2</sup> = 18.6	9, df = 7 (	P = 0.009)	; I <sup>2</sup> = 63%					•							
Test for overall effect: Z = 2	.84 (P = 0.0	05)							-2 -1 0 1 2							
Test for subgroup differences: Chi <sup>2</sup> = 1.06, df = 1 (P = 0.30), $I^2 = 5.3\%$								Favours	s [experimental] Favours [contro	ol]						
Risk of bias legend																

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 6. Subgroup analysis (direction of effect - increase or decrease). Outcome: cortisol (immediate).

	Spinal Manipulation (SM)			Control or Sham			Mean difference			Mean diff	Mean difference			Risk of Bias					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%	% CI	IV, Fixed,	95% CI	Α	в	С	D	EF	G		
1.9.1 neck pain																			
Christian 1988	-11.5	4.7	10	-9.6	3.8	10	0.0%	-1.90 [-5.65 ,	, 1.85]		_	•	•	• (	? (	• •	) ?		
Lohman 2019	10.8	7.18	13	13.97	6.84	15	0.0%	-3.17 [-8.39	, 2.05]		_	+ (	•	? (	•	• •	•		
Valera-Calero 2019	-0.73	0.05	28	-0.64	0.05	27	98.8%	-0.09 [-0.12 ,	-0.06]			•	Ŧ	• (	•	Ð (	2 😑		
Subtotal (95% CI)			51			52	98.8%	-0.09 [-0.12 ,	-0.06]										
Heterogeneity: Chi <sup>2</sup> = 2.2	24, df = 2 (P	= 0.33); l <sup>2</sup>	= 11%					-											
Test for overall effect: Z	= 6.69 (P < 0	0.00001)																	
1.9.2 AT																			
Sampath 2021	4.01	1.76	21	4.46	2.73	21	0.0%	-0.45 [-1.84	, 0.94]	_		•	Ŧ	•	<b>+</b> (	Ð G	•		
Subtotal (95% CI)			21			21	0.0%	-0.45 [-1.84 ,	0.94]	-									
Heterogeneity: Not appli	cable								-	1									
Test for overall effect: Z	= 0.63 (P = 0	0.53)																	
1.9.3 healthy																			
Plaza-Manzano 2014	-14.2	3.8	10	-9.6	3.1	10	0.0%	-4.60 [-7.64 ,	-1.56]			•	Ŧ	•	? (	<b>Ð</b> (	•		
Plaza-Manzano 2014a	-10.1	3.67	10	-9.6	3.1	10	0.0%	-0.50 [-3.48	, 2.48]			•	÷	•	? (	<b>Ð</b> (	•		
Sampath 2017	-0.93	0.29	12	-0.73	0.32	12	1.2%	-0.20 [-0.44	, 0.04]	-		•	Ŧ	• •	•	• •	•		
Whelan 2002	-13.3	7.4	10	-10.7	10	20	0.0%	-2.60 [-8.94	, 3.74]			•	?	•	? (	• •	•		
Subtotal (95% CI)			42			52	1.2%	-0.23 [-0.48 ,	0.01]										
Heterogeneity: Chi <sup>2</sup> = 8.8	57, df = 3 (P	= 0.04); 12	= 65%						-	1									
Test for overall effect: Z	= 1.89 (P = 0	0.06)																	
Total (95% CI)			114			125	100.0%	-0.09 [-0.12 ,	-0.07]										
Heterogeneity: Chi2 = 12	.38, df = 7 (f	P = 0.09);	<sup>2</sup> = 43%																
Test for overall effect: Z	= 6.86 (P < 0	0.00001)								-10 -5 0	5 10								
Test for subgroup differe	nces: Chi <sup>2</sup> =	1.58, df =	2 (P = 0.4	45), I² = 0%	6				Favour	rs [experimental]	Favours [control]								
Risk of bias legend																			
(A) Random sequence g	eneration (s	election bi	as)																

(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)

(D) Blinding of outcome assessment (detection bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Other bias

Figure 7. Sub-group analysis (healthy vs pain). Outcome: cortisol (immediate).

is better than control in influencing inflammatory markers such as interleukins (Table 4).

# Spinal manipulation (vs.) control in influencing endocrine biomarkers

#### Cortisol

Data was pooled from seven studies (239 participants) to determine the effects of SM on cortisol levels (Figure 4a). Between-study heterogeneity was moderate (I [2] = 63%). Hence a sensitivity analysis was done, and two studies were removed from the meta-analysis, which reduced the heterogeneity (I [2] = 0%) (Figure 4b) There was a 'low' quality evidence (Table 5) of statistically significant difference that SM is better than control/sham in eliciting changes in cortisol levels (SMD -0.42, 95% CI - 0.74 to - 0.10; PI - 0.83 to 0.0) immediately after intervention.

#### Segmental response

A subgroup analysis was undertaken to determine if the response in cortisol was different based on the region of spine manipulated (thoracic vs cervical in this instance). The results demonstrated that cervical spine manipulation cortisol levels compared to a thoracic spine manipulation (SMD- -0.65, 95% CI – 1.10 to -0.2; PI – 2.01 to 0.7) (refer Figure 5). **Direction of effect** Another subgroup analysis was undertaken to determine the direction of effect (increase or decrease) of cortisol following a spinal manipulation. The subgroup analysis indicates that cortisol levels increase immediately following a spinal manipulation despite the segment being manipulated (SMD -0.65, 95% CI -1.10 to -0.2; PI -2.08 to 0.79) (Figure 6).

#### Healthy vs painful population

Subgroup analysis demonstrated that changes in cortisol following an SM are statistically significant in people with pain (especially neck pain) compared to healthy volunteers (SMD -0.09, 95% Cl -0.12 to -0.07; PI -1.4 to 1.2) (Figure 7).

#### Cortisol (short-term)

Low-quality evidence from four studies (136 participants) demonstrated no significant difference that SM is better than control (SMD -0.45, 95% Cl -0.79 to -0.1; PI: -1.21 to 0.31) in eliciting changes in cortisol levels at short-term after intervention (Table 5). Although, the effect size and associated CIs indicate statistical significance, the prediction intervals are wide and point to lack of clear benefit from SM in short-term changes in cortisol.

#### Testosterone

Very Low' quality evidence from two studies (66 participants) demonstrated no significant difference that SM is better than control in eliciting changes in testosterone levels immediately (SMD -0.01, 95% Cl -0.14 to 0.12] and at short-term after intervention (SMD -0.04, 95% Cl -0.06 to 0.14] (Table 5). Findings from single studies indicate no change in epinephrine or norepinephrine and urinary pH level following spinal manipulation.

#### Discussion

#### Summary of main results

This review updates the previous review published in 2017 [59], comparing spinal manipulation against control in influencing biochemical markers. The updated review now includes 15 studies (737 participants) compared to eight studies (325 participants in the 2017 review). It also includes different types of participants (healthy volunteers, people in pain or disease); various types of spinal manipulation (cervical, thoracic and lumbar); a wide range of outcome measures (inflammatory markers, pain markers, urinary pH and T/C ratio), thus providing a comprehensive analysis of spinal manipulation in influencing biochemical markers. The findings from this review update established 'low' level evidence in support of SM in influencing biochemical markers such as cortisol (immediate changes) and inflammatory markers but not for substance-p, neurotensin, testosterone, oxytocin and orexin-A. Further, subgroup analyses established that: (1) cervical SM influences cortisol compared to thoracic SM; (2) cortisol levels increase immediately after intervention despite the segment being manipulated; and (3) response differs in people with pain (especially neck pain) compared to healthy volunteers. The key differences between the original review and this review update have been provided in appendix 1.

# Overall completeness and applicability of evidence

The data from this review can be considered relevant to current clinical practice as we found evidence that SM may influence various biochemical markers such as cortisol and inflammatory markers. It is important that these findings are interpreted with caution and in consideration of prediction intervals (discussed later). Further, 10 of studies out 15 [15,19,21,35,36,51,52,54,56,57] have been done on healthy volunteers, which makes it difficult to ascertain the applicability of the evidence in clinical practice. Although four studies [18,20,53,58] included participants with pain, the effect of SM on the magnitude and duration of biochemical responses in symptomatic patients

(e.g. pain population or inflammatory disorders) needs further scrutiny and is an ongoing area of investigation [20,35,58]. Cervical or thoracic spinal manipulation are the common techniques utilized in the studies, with a subgroup analysis demonstrating that cervical SM may have more influence on cortisol levels. However, this is based on five studies [18,36,53,56,58] and should be verified by future studies that may have direct comparison between the two techniques. There was no adverse events/harm associated with SM. One study <sup>51</sup>measured tissue damage markers and demonstrated that there was no tissue damage associated with SM.

### Quality of the evidence

As reflected by the GRADE ratings, the overall quality of the evidence in this review update was 'low' to 'very low' for all outcomes. This is because included trials studied a wide range of interventions, outcome measure, data collection techniques and post-intervention time points. Therefore, we were unable to pool data due to heterogeneity, especially for inflammatory markers. In addition, the sample size (being low in most studies), wide confidence intervals and prediction intervals led to issues of imprecision and inconsistency. It is important to note that we have downgraded the level of evidence compared to the original review. Although, eight more studies were part of this review update and points to growth in the evidence base, it also has resulted in further heterogeneity. Except for immediate changes in cortisol, the broad prediction intervals for other outcomes may indicate the existence of setting where SM may have suboptimal effects. Ten out of fifteen studies were small-scale RCTs (less than 50 participants) done on healthy volunteers where there is a chance for overly positive trends for interventions due to inflated effect sizes. A review [60] has shown that trials with fewer than 50 participants had effect estimates larger than trials with more participants (48% more on average). Hence, it has been recommended that trials with fewer than 19 participants in each trial arm be excluded from systematic reviews due to risk of bias associated with small RCTs [61]. We did not downgrade the risk of bias for blinding therapists as this is very difficult to achieve in manual therapy setting. While blinding of participants was done in some studies, it was unclear in other studies. Keeping in line with recent recommendations [62], future studies should concentrate on better blinding of participants and also therapists in maintaining blinding including adding a measure of blinding effectiveness. Only one study [58] had reported using the Template for Intervention Description and Replication (TIDieR) guidelines [63]. Therefore, it has to be reemphasized that the overall quality of reporting of manual therapy studies still requires considerable improvement.

# Potential biases in the review process

We consider the review process to be robust and expect minimal biases in extracting and reporting of data. A minimum of two reviewers acted independently through the various phases of the review and a third reviewer was available to resolve any disagreements if required. We undertook extensive search to identify new studies that may be included in this review update. We did not downgrade the risk of bias based on 'publication' bias as we had only 15 studies included in the review. It is well noted that existing ways to publication bias are unsatisfactory and funnel plot was not considered appropriate in this instance. Further, only publications done in English language were included in the review, thereby, raising the possibility of language bias [64]. In turn, this may limit the usefulness of the review's findings as we may miss out important cultural contexts [65]. Hence, recommendations have been made to include studies published in languages other than English (LOTE) [66]. However, due to lack of resources both in terms of funding and/or access to members who can fluently speak/ read LOTE, we had to limit our review to studies published only in English, as identified previously [64].

# Agreements and disagreements with other studies or reviews

The findings from this review update remain partly consistent with our original systematic review findings. However, we decided to downgrade the quality of evidence from 'low' to 'very low' compared to the original review, largely due to inconsistency, indirectness and imprecision introduced by the inclusion of these studies.

Our review update established very low evidence that SM does not influence neuropeptides such as SP, neurotensin, oxytocin and orexin-A immediately after intervention. This is in contrast with the previous findings [35,37,52]. These neuropeptides are found in many regions of the CNS and are known to induce analgesia directly or indirectly. Molina-Ortega et al. (2014) further reported a positive correlation between SP levels and pressure pain threshold suggesting that high levels of serum SP before SM are associated with increased pressure pain threshold after SM. Hence, the review findings may be of importance. It has to be noted however that only on a few studies [18,56] have investigated these neuropeptides. Hence, the lack of beneficial effects of SM may be due to low number of studies in this area highlighting the need for further research investigating these biomarkers.

Our review findings indicate the SM may influence cortisol levels immediately (<30 minutes) but not at short-term (many hours) after intervention. This is in

agreement with our original review that demonstrated changes in cortisol levels immediately but not at shortterm after intervention. The number of studies investigating the effects of SM on cortisol have increased in the last 5 years that may explain the difference. Emerging pattern from the current review update indicates that cortisol level may increase immediately after intervention despite the segment manipulated. However, this is based on only two studies [56,58] that had used a cervical spine manipulation involving rotational thrust. Further, a cervical spine manipulation may influence cortisol levels immediately in people with neck pain. The changes in cortisol were shown to be positively correlated with reduced neck pain and reduced disability in one study [58]. It was noted that recent studies have considered various methodological factors that may influence cortisol levels and have outlined strategies to mitigate these variables, which is consistent with previous recommendations [37,67].

Our review update demonstrated no significant difference that SM is better than control in eliciting changes in testosterone levels immediately and at short-term after intervention. Testosterone was measured in the studies as interactions between the end products of the gonadal (e.g. testosterone) and the adrenal axis (cortisol) have been well documented [68]. Hence, the balance between testosterone and cortisol represented as T/C ratio may therefore provide a better estimation of the HPA axis activity [69]. Although not often used in manual therapy research, T/C ratio has been widely used in sports and exercise science research as valid outcome measure for stress response [69]. Hence, T/C ratio is an area of future research interest.

Findings from our review of four studies indicate that SM is better than control in influencing various inflammatory/immune markers such as interleukins (especially, IL-1, IL-2, IL-6), TNF-α, IgG and IgM. The regulation of inflammation and immunity involve complex interactions between the nervous system and the immune system mediated by the action of numerous neurotransmitters and cytokines [29,30,70]. This is consistent with previous findings and suggest that a central anti-inflammatory mechanism might be activated following a SM. However, it must be noted that some of the studies were done more than 10 years previously indicating a dearth of recent investigation in this area. Hence, our findings must be interpreted with caution.

# Implications for clinical practice and research

Two common themes are consistent with our previous systematic review (1) clinical utility: while the changes in endocrine markers (especially cortisol) and inflammatory markers shed light into mechanisms through which SM may work, the clinical utility of such changes (especially short-term) is still largely unknown. Hence, it will be helpful to investigate long-term changes in these biochemical markers and their association with symptom improvement. (2) The mean age of participants explored across studies was 29.2 year (up from 26 years in the original review). Therefore, the generalizability and clinical application of our findings could be questioned. Hence, future studies may target participants across different age groups. The methodology used for collecting hormone samples and the reporting of protocol have improved since our previous review.

The wider prediction interval found in our metaanalysis may have important implication for clinical practice and research. Despite statistically significant findings as demonstrated by effect size and confidence intervals, the wide prediction intervals reduce the confidence in findings. That is, the effects of intervention may vary substantially depending on the setting or population used. This clearly emphasizes the need for more well controlled studies to clarify our findings. The rationale for calculating prediction intervals could be criticized as there are less than ten studies as part of our meta-analysis [47]. However, we decided to calculate prediction intervals for a few reasons (1) there is still no consensus on what a sufficient number of studies would be to generate reliable prediction intervals. Some evidence [46] indicate that a minimum of three studies is enough to calculate prediction intervals (which we meet); (2) it is important to demonstrate the variability/heterogeneity to enable meaningful interpretation of our findings by clinicians and researchers; and (3) it is better to highlight the heterogeneity and therefore the need for further research than to erroneously conclude that the intervention is beneficial (as demonstrated by effect size and CIs alone). Finally, we did not propose GRADE-based recommendations due to the heterogeneity, which can be considered another important limitation.

# **Author's Conclusion**

This review established low-level evidence that SM influences various inflammatory markers and cortisol. Specifically, we found that SM can increase cortisol levels immediately post-intervention. Hence the beneficial effects of SM such as pain relief and reduced inflammation could potentially be modulated through these mechanistic pathways. However, well-powered trials targeting symptomatic populations are required to validate our review findings.

# **Disclosure statement**

No potential conflict of interest was reported by the author(s).

#### Funding

The author(s) reported there is no funding associated with the work featured in this article.

#### **Notes on contributors**

*Kesava Kovanur Sampath* is a Principal Academic Staff Member in the Centre for Health and Social Practice at Waikato Institute of Technology in New Zealand. He is the chair of the osteopathic research steering committee in New Zealand. He is part of the leadership team at the Duke Centre of Excellence in Manual and Manipulative Therapy. He is also a visiting research fellow at the University of Technology, Sydney. Kesava's research specialties include neurophysiological outcomes, spinal manipulation, manual therapy practice and education.

*Dr Loïc Treffel* is a Principal Investigator of ALGOS project: Osteopathy in Oncology (NCT05726929 Study Record | Beta ClinicalTrials.gov). He is a Ph.D. Researcher in Space Physiology on vertebral deconditioning. Scientist Principal Investigator supported by CNES (French Space Agency). PhD. Thesis defended in 2017 Life Sciences and Health, Vertebral Dysfunctions and Postural changes after microgravity simulation studies. University of Strasbourg, IPHC-CNRS (UMR7178, ED 414).

**Dr Oliver P.Thomson** is an Associate Professor at the University College of Osteopathy where he leads the Doctoral Programme, and he works clinically as an osteopath in London. Oliver has a particular interest in qualitative research methodologies to explore the clinical and theoretical aspects of osteopathy and musculoskeletal practice such as the areas of clinical decision-making and the role of evidence-base practice. He has over 50 peer-reviewed publication in these areas. Oliver examines and supervises PhD students in the UK and Australia and collaborates with national and international colleagues on numerous research projects.

*Dr Jerry Draper-Rodi* is the Director of the National Council for Osteopathic Research (NCOR) in the UK, a Senior Research Fellow at the University College of Osteopathy (UCO), a visiting fellow on the international osteopathic research leadership programme (UTS School of Public Health, Australia) and a clinician. Jerry's research streams include: knowledge mobilisation; Research methods in complex interventions; and Equity, Diversity and Inclusion (EDI).

**Dr Michael Fleischmann** has over 25 peer-reviewed publications. His research focus can be conceptualised as 3 main areas: 1. evaluation of education intervention; 2. Epidemiology, particularly in osteopathy and manual therapies; 3. clinical reasoning of manual therapists. Michael's wide range of experience in educational and clinical settings displays an exceptional ability to work with a high degree of productivity with students as a core focus. He embraces diversity and welcomes opportunities to work with a broad range of disciplines and specialties. His teaching practice focusses on constantly engaging with students and other staff to provide rich learning experiences.

**SteveTumilty** is one of the few clinician scientists in Physiotherapy Worldwide and one of the few Registered Physiotherapy Specialists in New Zealand. The majority of his clinical experience has been in the outpatient musculoskeletal practice setting in UK, Germany and New Zealand. He also has experience in professional sports and Occupational Health Physiotherapy. In 2002 he came to work at the School of Physiotherapy, Otago University and he has developed and coordinated the specialist Masters degree for Sports and Orthopaedic Manipulative Therapy for which he provides teaching and clinical expertise. He is the author or coauthor on 125 research outputs in the field of Physiotherapy and Orthopaedic Manipulative Therapy for musculoskeletal conditions and has been invited to present at international conferences. He has taught manual therapy seminars in New Zealand and Japan. Associate Professor Tumilty's research interests are in Tendinopathy, modulation of the Hypothalamus-Pituitary Axis using manual interventions, and the influence of the autonomic nervous system on musculoskeletal pain and healing.

#### References

- Coronado RA, Gay CW, Bialosky JE, et al. Changes in pain sensitivity following spinal manipulation: a systematic review and meta-analysis. J Electromyogr Kinesiol. 2012;22(5):752–767. doi: 10. 1016/j.jelekin.2011.12.013
- Bonic EE, Stockwell CA, Kettner NW. Brain stem compression and atlantoaxial instability secondary to chronic rheumatoid arthritis in a 67-year-old female. J Manipulative Physiol Ther. 2010;33(4):315–320. doi: 10.1016/j.jmpt.2010.03.008
- [3] Brosseau L, Wells GA, Poitras S, et al. Ottawa panel evidence-based clinical practice guidelines on therapeutic massage for low back pain. J Bodyw Mov Ther. 2012;16(4):424–455. doi: 10.1016/j.jbmt.2012.04.002
- [4] Gross A, Miller J, D'Sylva J, et al. Manipulation or mobilisation for neck pain: a Cochrane review. Manual Ther. 2010;15(4):315–333. doi: 10.1016/j. math.2010.04.002
- [5] Martin SL, Kerr KL, Bartley EJ, et al. Respiration-induced hypoalgesia: exploration of potential mechanisms. *J Pain*. 2012;13(8):755–763. doi: 10.1016/j.jpain.2012. 05.001
- [6] Coppieters MW, Butler DS. Do 'sliders' slide and 'tensioners' tension? An analysis of neurodynamic techniques and considerations regarding their application. Manual Ther. 2008;13(3):213–221. doi: 10.1016/j.math. 2006.12.008
- [7] Bialosky JE, Bishop MD, Price DD, et al. The mechanisms of manual therapy in the treatment of musculoskeletal pain: a comprehensive model. Manual Ther. 2009;14(5):531–538. doi: 10.1016/j.math.2008.09.001
- [8] Wellens F. The traditional mechanistic paradigm in the teaching and practice of manual therapy: time for a reality check. 2010.
- [9] Bakhtadze MA, Vernon H, Karalkin AV, et al. Cerebral perfusion in patients with chronic neck and upper back pain: preliminary observations. J Manipulative Physiol Ther. 2012;35(2):76–85. doi: 10.1016/j.jmpt. 2011.12.006
- [10] Chu J, Allen DD, Pawlowsky S, et al. Peripheral response to cervical or thoracic spinal manual therapy: an evidence-based review with meta analysis. *J Manual Manipulative Ther*. 2014;22(4):220–229. doi: 10.1179/2042618613y.000000062
- [11] Eisold S, Mehrabi A, Konstantinidis L, et al. Experimental study of cardiorespiratory and stress factors in esophageal surgery using robot-assisted thoracoscopic or open thoracic approach. Arch Surg. 2008;143(2):156–163. doi: 10.1001/archsurg.2007.56

- [12] Kingston L, Claydon L, Tumilty S. The effects of spinal mobilizations on the sympathetic nervous system: a systematic review. Manual Ther. 2014;19 (4):281–287. doi: 10.1016/j.math.2014.04.004
- [13] Matus S, Valenzuela V, Medinas DB, et al. ER dysfunction and protein folding stress in ALS. Int J Cell Biol. 2013;2013:1–12. doi: 10.1155/2013/674751
- [14] Moutzouri M, Joanna P, Eudokia B. Investigation of the effects of a centrally applied lumbar sustained natural apophyseal glide mobilization on lower limb sympathetic nervous system activity in asymptomatic subjects. J Manipulative Physiol Ther. 2012;35 (4):286–294. doi: 10.1016/j.jmpt.2012.04.016
- [15] Puhl AA, Injeyan HS. Short-term effects of manipulation to the upper thoracic spine of asymptomatic subjects on plasma concentrations of epinephrine and norepinephrine—A Randomized and controlled Observational study. J Manipulative Physiol Ther. 2012;35(3):209–215. doi: 10.1016/j.jmpt.2012.01.012
- [16] Schmid A, Brunner F, Wright A, et al. Paradigm shift in manual therapy? Evidence for a central nervous system component in the response to passive cervical joint mobilisation. Manual Ther. 2008;13(5):387–396. doi: 10.1016/j.math.2007.12.007
- [17] Wingenfeld K, Heim C, Schmidt I, et al. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom Med. 2008;70(1):65–72. doi: 10.1097/PSY. 0b013e31815ff3ce
- [18] Lohman EB, Pacheco GR, Gharibvand L, et al. The immediate effects of cervical spine manipulation on pain and biochemical markers in females with acute non-specific mechanical neck pain: a randomized clinical trial. *J Manual Manipulative Ther.* 2019;27 (4):186–196. doi: 10.1080/10669817.2018.1553696
- [19] Sampath KK, Botnmark E, Mani R, et al. Neuroendocrine response following a thoracic spinal manipulation in healthy men. J Orthop Sports Phys Ther. 2017;47(9):617–627. doi: 10.2519/jospt.2017. 7348
- [20] Sampath KK, Mani R, Katare R, et al. Thoracic spinal manipulation effect on neuroendocrine response in people with Achilles tendinopathy: a randomized crossover trial. J Manipulative Physiol Ther. 2021;44 (5):420–431. doi: 10.1016/j.jmpt.2021.06.001
- [21] Teodorczyk-Injeyan JA, McGregor M, Ruegg R, et al. Interleukin 2-regulated in vitro antibody production following a single spinal manipulative treatment in normal subjects. *Chiropr Man Therap.* 2010;18(1):1. doi: 10.1186/1746-1340-18-26
- [22] Gevers-Montoro C, Provencher B, Descarreaux M, et al. Neurophysiological mechanisms of chiropractic spinal manipulation for spine pain. *Eur J Pain*. 2021;25 (7):1429–1448. doi: 10.1002/ejp.1773
- [23] Haavik H, Kumari N, Holt K, et al. The contemporary model of vertebral column joint dysfunction and impact of high-velocity, low-amplitude controlled vertebral thrusts on neuromuscular function. *Eur J Appl Physiol*. 2021;121(10):2675–2720. doi: 10.1007/s00421-021-04727-z
- [24] Lutke Schipholt IJ, Coppieters MW, Meijer OG, et al. Effects of joint and nerve mobilisation on neuroimmune responses in animals and humans with neuromusculoskeletal conditions: a systematic review and meta-analysis. Pain Rep. 2021;6(2):e927. doi: 10.1097/ pr9.000000000000927

- [25] Wirth B, Gassner A, de Bruin ED, et al. Neurophysiological effects of high velocity and low amplitude spinal manipulation in symptomatic and asymptomatic humans: a systematic literature review. Spine. 2019;44(15):E914–E926. doi: 10.1097/BRS. 000000000003013
- [26] Takuwa H, Matsuura T, Bakalova R, et al. Contribution of nitric oxide to cerebral blood flow regulation under hypoxia in rats. J Physiol Sci. 2010;60(6):399–406. doi: 10.1007/s12576-010-0108-9
- [27] Dobner PR. Neurotensin and pain modulation. Peptides. 2006;27(10):2405–2414. doi: 10.1016/j.pep tides.2006.04.025
- [28] Nicoletti M, Neri G, Maccauro G, et al. Impact and neuropeptide substance P an inflammatory compound on arachidonic acid compound generation. Int J Immunopathol Pharmacol. 2012;25(4):849–857. doi: 10.1177/039463201202500403
- [29] Lotz M, Vaughan JH, Carson DSA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science. 1988;241 (4870):1218–1221. doi: 10.1126/science.2457950
- [30] Suffredini AF, Fantuzzi G, Badolato R, et al. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19(4):203–214. doi: 10.1023/A:1020563913045
- [31] Elenkov IJ, Wilder RL, Chrousos GP, et al. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 2000;52(4):595–638.
- [32] Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5(7):374–381. doi: 10.1038/ nrendo.2009.106
- [33] Priftis KN, Papadimitriou A, Anthracopoulos MB, et al. Endocrine-immune interactions in adrenal function of asthmatic children on inhaled corticosteroids. Neuroimmunomodulation. 2009;16(5):333–339. doi: 10.1159/000216191
- [34] Degenhardt BF, Darmani NA, Johnson JC, et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. J Am Osteopath Assoc. 2007;107(9):387–400. http://www.scopus.com/inward/record.url?eid=2-s2.0-34948818710&partnerlD=40&md5=257097abc17ab76422809bfb21c045e3
- [35] Molina-Ortega F, Lomas-Vega R, Hita-Contreras F, et al. Immediate effects of spinal manipulation on nitric oxide, substance P and pain perception. Manual Ther. 2014;19(5):411–417. doi: 10.1016/j.math.2014.02.007
- [36] Whelan TL, Dishman JD, Burke J, et al. The effect of chiropractic manipulation on salivary cortisol levels. J Manipulative Physiol Ther. 2002;25(3):149–153. http://search.ebscohost.com/login.aspx?direct= true&db=cin20&AN=2002089945&site=ehostlive&scope=site
- [37] Sampath KK, Mani R, Cotter J, et al. Reply to letter to the editor 'changes in biochemical markers following spinal manipulation – a systematic review and metaanalysis'. Musculoskeletal Sci Pract. 2017;30:e90. doi: 10.1016/j.msksp.2017.04.004
- [38] Garner P, Hopewell S, Chandler J, et al. When and how to update systematic reviews: consensus and checklist. BMJ. 2016;354:i3507. doi: 10.1136/bmj.i3507

- [39] Smith GD, Ho KHM. Systematic reviews: when should they be updated? J Clin Nurs. 2023;32(9–10):e17–e18. doi: 10.1111/jocn.16547
- [40] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann internal med. 2009;151 (4):264–269. doi: 10.7326/0003-4819-151-4-200908180-00135
- [41] Conway PJW, Herzog W, Zhang Y, et al. Forces required to cause cavitation during spinal manipulation of the thoracic spine. Clin Biomech. 1993;8(4):210–214. doi: 10.1016/0268-0033(93)90016-B
- [42] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2): d5928. doi: 10.1136/bmj.d5928
- [43] Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898
- [44] Version 1.22.0: The Cochrane Collaboration; 2020.
- [45] Cohen J. Statistical power analysis for the behavioral sciences. revised ed. New York: Academic Press; 1977.
- [46] Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25(6):646–654. doi: 10.1177/ 0272989x05282643
- [47] Borenstein M. Research note: in a meta-analysis, the l2 index does not tell us how much the effect size varies across studies. J Physiother. 2020;66(2):135–139. doi: 10.1016/j.jphys.2020.02.011
- [48] Joanna I, John PAI, Maroeska MR, et al. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6(7):e010247. doi: 10.1136/bmjopen-2015-010247
- [49] Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137–159. doi: 10.1111/j.1467-985X.2008.00552.x
- [50] Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336 (7650):924–926. doi: 10.1136/bmj.39489.470347.AD
- [51] Achalandabaso A, Plaza-Manzano G, Lomas-Vega R, et al. Tissue damage markers after a spinal manipulation in healthy subjects: a preliminary report of a randomized controlled trial. Dis Markers. 2014;2014:1–7. doi: 10.1155/ 2014/815379
- [52] Brennan PC, Kokjohn K, Kaltinger CJ, et al. Enhanced phagocytic cell respiratory burst induced by spinal manipulation: potential role of substance P. J Manipulative Physiol Ther. 1991;14(7):399–408.
- [53] Christian GF, Stanton GJ, Sissons D, et al. Immunoreactive ACTH, β-endorphin, and cortisol levels in plasma following spinal Manipulative therapy. Spine. 1988;13(12):1411–1417. doi: 10.1097/00007632-198812000-00014
- [54] Duarte FCK, Funabashi M, Starmer D, et al. Effects of distinct force magnitude of spinal manipulative therapy on blood biomarkers of inflammation: a proof of principle study in healthy young adults. J Manipulative Physiol Ther. 2022;45(1):20–32. doi: 10.1016/j.jmpt. 2022.03.012
- [55] Pascual-Vaca Á O, Punzano-Rodríguez R, Escribá-Astaburuaga P, et al. Short-term changes in algo-

metry, inclinometry, stabilometry, and urinary pH Analysis after a thoracolumbar junction manipulation in patients with kidney stones. J Altern Complementary Med. 2017;23(8):639–647. http:// ezproxy.canberra.edu.au/login?url=https://search. ebscohost.com/login.aspx?direct=true&db= asn&AN=124584232.

- [56] Plaza-Manzano G, Molina F, Lomas-Vega R, et al. Changes in biochemical markers of pain perception and stress response after spinal manipulation. J Orthop Sports Phys Ther. 2014;44(4):231–239. doi: 10.2519/jospt.2014.4996
- [57] Teodorczyk-Injeyan JA, Injeyan HS, Ruegg R. Spinal manipulative therapy reduces inflammatory cytokines but not substance P production in normal subjects. J Manipulative Physiol Ther. 2006;29(1):14–21. doi: 10. 1016/j.jmpt.2005.10.002
- [58] Valera-Calero A, Lluch Girbes E, Gallego-Izquierdo T, et al. Endocrine response after cervical manipulation and mobilization in people with chronic mechanical neck pain: a randomized controlled trial. Eur J Phys Rehabil Med. 2019;55(6):792–805. doi: 10.23736/ S1973-9087.19.05475-3
- [59] Sampath KK, Mani R, Cotter JD, et al. Measureable changes in the neuro-endocrinal mechanism following spinal manipulation. Med Hypotheses. 2015;85 (6):819–824. doi: 10.1016/j.mehy.2015.10.003
- [60] Dechartres A, Trinquart L, Boutron I, et al. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ. 2013;346:f2304. doi: 10.1136/bmj.f2304
- [61] de C Williams AC, Fisher E, Hearn L, et al. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. 2020;2020(8). doi: 10.1002/14651858.CD007407.pub4
- [62] Hohenschurz-Schmidt D, Vase L, Scott W, et al. Recommendations for the development, implementation, and reporting of control interventions in efficacy and mechanistic trials of physical, psychological, and

self-management therapies: the CoPPS statement. BMJ. 2023;381:e072108. doi: 10.1136/bmj-2022-072108

- [63] Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348(mar07 3):g1687. doi: 10.1136/ bmj.g1687
- [64] Neimann Rasmussen L, Montgomery P. The prevalence of and factors associated with inclusion of non-English language studies in campbell systematic reviews: a survey and meta-epidemiological study. Syst Rev. 2018;7(1):129. doi: http://dx.doi.org/10.1186/ s13643-018-0786-6
- [65] Walpole SC. Including papers in languages other than English in systematic reviews: important, feasible, yet often omitted. J Clin Epidemiol. 2019;111:127–134. doi: 10.1016/j.jclinepi.2019.03.004
- [66] Kugley S, Wade A, Thomas J, et al. Searching for studies: a guide to information retrieval for campbell. Campbell Syst Rev. 2016;13(1):1–73. doi: 10.4073/ cmg.2016.1
- [67] Stalder T, Kirschbaum C, Kudielka BM, et al. Assessment of the cortisol awakening response: expert consensus guidelines. Psychoneuroendocrinology. 2016;63:414–432. doi: 10.1016/j.psyneuen.2015.10.010
- [68] Bedgood D, Boggiano MM, Turan B. Testosterone and social evaluative stress: The moderating role of basal cortisol. Psychoneuroendocrinology. 2014;47:107–115. doi: 10.1016/j.psyneuen.2014.05.007
- [69] Hayes LD, Grace FM, Baker JS, et al. Exercise-induced responses in Salivary testosterone, cortisol, and their ratios in men: a meta-analysis. Sports Med. 2015;45 (5):713–726. doi: 10.1007/s40279-015-0306-y
- [70] Goebel MU, Mills PJ, Irwin MR, et al. Interleukin-6 and tumor necrosis factor-α production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways. Psychosom Med. 2000;62(4):591–598. doi: 10.1097/00006842-200007000-00019